aTyr Pharma, Inc.
ATYR
$0.53
-$0.03-5.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 22.72% | 45.76% | -31.81% | -31.26% | 0.58% |
| Total Depreciation and Amortization | 0.00% | 1.29% | 0.52% | 1.04% | 38,400.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.17% | 5.04% | -6.26% | 29.36% | 202.78% |
| Change in Net Operating Assets | -687.22% | -86.78% | -7.22% | 379.26% | -197.35% |
| Cash from Operations | -2.63% | 40.44% | -47.37% | 9.90% | -17.42% |
| Capital Expenditure | -345.16% | 16.22% | -311.11% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.34% | 180.93% | -714.50% | 174.89% | 27.15% |
| Cash from Investing | -30.10% | 180.69% | -717.30% | 174.68% | 27.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.16% | -2.21% | -2.26% | -1.53% | -2.34% |
| Issuance of Common Stock | -- | -99.97% | 65.02% | -3.89% | -1.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -8.40% | -100.44% | 65.49% | -3.92% | -1.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -128.30% | 136.63% | -253.83% | 702.64% | -220.63% |